The power to change minds
By correcting disease at its source, we remedy its diverse impacts, for significantly improved outcomes.
Conventional medicine for neurological disease has limitations
Current treatments target individual symptoms only. These have minimal impact, which can diminish over time, even with increasing dosages. Most are powerless against some diseases, and in turn, often cause side effects as debilitating as the disease itself.
At Neumirna, we’re taking a different approach — targeting the disease at its root, in the context of the whole patient. Our miRNA therapeutics work by restoring cellular function, guiding cells back to their healthy state. Administered in small doses, typically once or twice a year, the therapy is designed for minimal side effects, physician oversight, and straightforward monitoring via blood and spinal fluid tests.
Early results are compelling, showing potential to halt, reverse, or even cure diseases once thought untreatable. We are advancing this new class of medicine with urgency, aiming to restore health and quality of life to patients with serious neurological diseases.
Clinical trials of our lead asset for epilepsy are set to start in 2026
If you're discouraged with current treatment options, we believe we can change your mind.
A better outlook for people with neurological disease
As we advance the development of our miRNA-based therapies, we aim to deliver transformative benefits for patients where other treatments have failed, lost effectiveness, or caused significant side effects.
- Disease modification at its source: Our treatments target the underlying cause, with the potential to slow, halt, reverse or even cure neurological diseases.
- Comprehensive impact: Recognizing that disease affects the whole person, our approach addresses the full spectrum of disease consequences, rather than isolated symptoms.
- Targeted precision: Delivered directly to the central nervous system in small, highly specific doses, our therapy selectively engages diseased cells in the brain while minimizing side effects.
- Clinician-administered for safety and monitoring: Treatments are delivered by medical professionals in controlled clinical settings, enabling careful monitoring of efficacy and safety.
- Long-lasting effect: Our therapy requires administration only once or twice per year, greatly reducing the treatment burden on patients. Unlike many conventional drugs that lose effectiveness over time, our approach maintains its impact without requiring increasing dosages to remain effective.
